|
4th International AIDS Society Conference on HIV Pathogenesis and TreatmentSydney, Australia - July 22 - 25, 2007 |
TRENDS AND PREDICTORS OF HIV-ASSOCIATED RISK BEHAVIORS AMONG INJECTING DRUG USERS PARTICIPATING IN AN HIV PREVENTION TRIAL, BANGKOK
IAS Conf HIV Pathog Treat 2007 Jul 22-25;4th: Abstract No. MOAC201
Vanichseni S.1, Martin M.2, Suntharasamai P.1, Sangkum U.1, van Griensven F.2, Mock P.2, Chuachoowong R.2, Leethochawalit M.3, Chiamwongpaet S.3, Choopanya K.1
1Bangkok Tenofovir Study Group, Bangkok, Thailand, 2Thailand MOPH - U.S. CDC Collaboration, Nonthaburi, Thailand, 3Bangkok Metropolitan Administration, Bangkok, Thailand
OBJECTIVES: The Bangkok Tenofovir Study (BTS) is a phase II/III, randomized, placebo-controlled, double-blind study being conducted in 17 Bangkok Metropolitan Administration drug treatment clinics to determine if tenofovir is safe and if it prevents HIV infection among injecting drug users (IDUs). At the clinics, IDUs receive risk reduction counseling and have access to methadone treatment, condoms, and bleach with instructions on how to clean needles, all free of charge. To assess the effectiveness of these risk reduction activities, we examined the prevalence and potential predictors of risk behaviors during study follow-up.
METHODS: Participant demographic characteristics and risk behaviors (i.e., injecting drugs, sharing needles/syringes) were assessed at enrollment and risk behaviors every 3 months thereafter. The proportion of participants who reported injecting drugs and sharing needles and/or syringes was compared at months 0, 3, 6, 9, and 12. Generalized estimation logistic regression analysis was used to identify predictors of injecting and sharing.
RESULTS: From June 2005 through December 2006, 1,465 participants enrolled; median age was 31 years, 79% were male, and 48% had a primary education (6 years of schooling) or less. Risk data were available on 1,455. At enrollment 919 (63%) reported injecting and 238 (16%) reported sharing in the past 3 months. Reported injection and sharing decreased at month 3 (injection 31%, sharing 3%) and remained steady through month 12 (both p<0.0001). Overall, 558 (38%) injected methamphetamine, 431 (30%) midazolam, and 425 (29%) heroin. Age >26 years, >6 years of education, and male sex were independent predictors of injecting (all p<0.0001); male sex (p<0.001) was a predictor of sharing.
CONCLUSIONS: BTS participants reported decreased risk behavior during trial follow-up but remain at risk for HIV infection. There is an urgent need for effective biological and behavioral interventions to prevent HIV infection of IDUs.
Download PDF of this abstract.
Download Power Point Presentation.
2007-07-22
MOAC201
Global Responses to HIV Prevention Among Injection Drug Users
Copyright © 2007 - International AIDS Society (IAS). All information and content relating to the abstracts from the 3rd International AIDS Society Conference on HIV Pathogenesis and Treatment, such as text, graphics, logos, button icons, images, audio clips, and software is protected by copyright. Permission is hereby granted for the non-commercial use or reproduction of the information on this web site, provided that the use of such information is accompanied by an acknowledgement that IAS is the source of the information and the name of the author of the article.
AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 2007. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 2007. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. Permission is hereby granted for the non-commercial use or reproduction of the information herein, provided that the use of such information is accompanied by an acknowledgement that IAS is the source of the information and the name of the author of the article.